Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia
KL Chohan, P Kapoor - Current Hematologic Malignancy Reports, 2024 - Springer
Abstract Purpose of Review Waldenström macroglobulinemia is a rare non-Hodgkin
lymphoma (NHL) characterized by lymphoplasmacytic bone marrow infiltration associated …
lymphoma (NHL) characterized by lymphoplasmacytic bone marrow infiltration associated …
[HTML][HTML] The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer
Highlights•Synergistic COVID-19-and oncologic disease-mediated inflammation may drive
mortality in patients with cancer and COVID-19.•Inflammation is not only a prognostic …
mortality in patients with cancer and COVID-19.•Inflammation is not only a prognostic …
Mouse models of human multiple myeloma subgroups
W Winkler, C Farré Díaz, E Blanc… - Proceedings of the …, 2023 - National Acad Sciences
Multiple myeloma (MM), a tumor of germinal center (GC)-experienced plasma cells,
comprises distinct genetic subgroups, such as the t (11; 14)/CCND1 and the t (4; 14)/MMSET …
comprises distinct genetic subgroups, such as the t (11; 14)/CCND1 and the t (4; 14)/MMSET …
Transcriptome analysis of diffuse large b-cell lymphoma cells inducibly expressing MyD88 L265P mutation identifies upregulated CD44, LGALS3, NFKBIZ, and BATF …
M Turi, A Anilkumar Sithara, L Hofmanová… - International Journal of …, 2023 - mdpi.com
During innate immune responses, myeloid differentiation primary response 88 (MyD88)
functions as a critical signaling adaptor protein integrating stimuli from toll-like receptors …
functions as a critical signaling adaptor protein integrating stimuli from toll-like receptors …
Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population‐based study in The Netherlands …
K Amaador, MJ Kersten, O Visser… - British journal of …, 2022 - Wiley Online Library
It is unclear how treatment advances impacted the population‐level survival of patients with
lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia (LPL/WM). Therefore, we …
lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia (LPL/WM). Therefore, we …
Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments
B Hu, KP Patel, HC Chen, X Wang… - British Journal of …, 2019 - Wiley Online Library
Chronic lymphocytic leukaemia (CLL) is a genetically heterogeneous disease characterised
by genomic alterations and gene mutations that may portend worse survival or resistance to …
by genomic alterations and gene mutations that may portend worse survival or resistance to …
Incidence, prevalence, mortality, and causes of death in Waldenström macroglobulinemia: a nationwide, population-based cohort study
S Jeong, SG Kong, DJ Kim, S Lee, HS Lee - BMC cancer, 2020 - Springer
Background The epidemiological features of Waldenström macroglobulinemia (WM) have
seldom been investigated at a national level, particularly in East Asia. The goal of our study …
seldom been investigated at a national level, particularly in East Asia. The goal of our study …
Monoclonal gammopathy of undetermined significance: a comprehensive review
J Kaur, SS Valisekka, M Hameed, PS Bandi… - … Myeloma and Leukemia, 2023 - Elsevier
Abstract Monoclonal Gammopathy of Undetermined Significance (MGUS) is an
asymptomatic premalignant plasma cell dyscrasia with a predominate rise of the IgG …
asymptomatic premalignant plasma cell dyscrasia with a predominate rise of the IgG …
Current and emerging treatments for Waldenström macroglobulinemia
CN Grimont, NE Castillo Almeida, MA Gertz - Acta Haematologica, 2021 - karger.com
Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma. The primary
goal of therapy is to reduce symptoms related to direct infiltration of the bone marrow and …
goal of therapy is to reduce symptoms related to direct infiltration of the bone marrow and …
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's …
P Panayiotidis, G Tumyan, C Thieblemont… - Leukemia & …, 2022 - Taylor & Francis
We report efficacy, safety and biomarker data from a phase-II study evaluating atezolizumab
(eight 21-day cycle as induction therapy) in combination with obinutuzumab in patients with …
(eight 21-day cycle as induction therapy) in combination with obinutuzumab in patients with …